Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Icon, Anthropic partner to deploy Claude AI into clinical trials via multi-year collaboration
Research collaboration, AI/ML, clinical trials, drug discovery, R&D - Read more

AstraZeneca, CSPC Pharmaceutical form joint venture for biologics manufacturing in China
Joint venture, biologics, manufacturing, AI/ML, equity investment - Read more

Arrowhead Pharmaceuticals acquires FDA Rare Pediatric Disease Priority Review Voucher for plozasiran sHTG sNDA submission
Priority review voucher, rare disease, small molecule, regulatory, cardiovascular - Read more

Amplia Therapeutics, Eli Lilly collaborate to evaluate narmafotinib plus olomorasib combination in non-small cell lung cancer
Research collaboration, oncology, small molecule, non-small cell lung cancer - Read more

Evexta Bio, Roche collaborate on Phase 1b study combining rupitasertib with giredestrant for metastatic breast cancer
Clinical trial collaboration, oncology, small molecule, supply agreement - Read more

Phylo, Chugai Pharmaceutical partner to deploy Biomni Lab AI platform across drug discovery workflows
Research collaboration, AI/ML, drug discovery, R&D - Read more

From genomics to medical imaging to research, innovation needs the right data at the right time.

One global data fabric. Seamless collaboration. Access your data anywhere across on-premises, cloud, and edge.

Qumulo’s Life Sciences solution is enabling cutting-edge research in medicine and pharma. Explore the solution today.

NueCell Bio launches as specialized cell therapy translational partner, accelerating treatments from discovery to GMP manufacturing
Cell therapy, oncology, autoimmune, operational - Read more

Amgen's Repatha surges 37% in Q2 driven by cardiovascular risk reduction data momentum
Monoclonal antibody, cardiovascular, revenue impact, competitive - Read more

Gilead Sciences' HIV prevention franchise surpasses $1B quarterly sales, raises full-year HIV growth guidance
Small molecule, infectious disease, revenue impact, financial - Read more

Eli Lilly posts record $23B Q2 revenue, driven by Mounjaro and Zepbound despite slower Foundayo launch
Small molecule, metabolic disease, revenue impact, competitive - Read more

Amgen reports 10% revenue growth to $10.1B, bullish on Repatha despite new oral competitor
Small molecule, cardiovascular, financial, competitive - Read more

Expedition Therapeutics raises $115M Series B to advance COPD drug licensed from China
Respiratory disease, small molecule, COPD, clinical-stage - Read more

Mironid raises $46M Series B to advance rare kidney disease drug toward clinic
Rare disease, small molecule, kidney disease, preclinical - Read more

Basilea Pharmaceutica receives additional $5.4M BARDA funding to advance novel oral antibiotic ceftibuten-ledaborbactam
Infectious disease, small molecule, antibiotic, clinical-stage - Read more

CND Life Sciences closes undisclosed growth funding to expand Syn-One neurodiagnostics platform
Neurodiagnostics, biomarker discovery, neurological, neurodegenerative disease, diagnostics platform - Read more

Attovia Therapeutics raises $289M IPO to advance anti-itch biologic ATTO-1310 into Phase 2
Dermatology, biologic, IL-31, chronic pruritus, clinical-stage - Read more

Grace Therapeutics plans $10M private placement to advance GTx-104 nimodipine formulation for aSAH
Neurological, small molecule, clinical-stage, aSAH - Read more

Gilead Sciences wins California Supreme Court ruling, dismissing HIV drug negligence claims in landmark precedent
Small molecule, HIV, regulatory, competitive - Read more

Pfizer CEO defends $7B bolt-on M&A strategy, pledging dividend maintenance amid peer acquisition frenzy
M&A strategy, oncology, financial, cost reduction, strategic - Read more

Novo Nordisk CEO backs innovation as company's survival strategy amid recent pipeline setbacks
Small molecule, cardiovascular, strategic, competitive - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Novo Nordisk's CagriSema (cagrilintide/semaglutide), GLP-1/amylin combo, misses Ph3 blood sugar endpoint in type 2 diabetes vs. tirzepatide
Protein therapy, metabolic, cardiovascular, combination therapy, type 2 diabetes, GLP-1 - Read more

Eli Lilly drops Ph1/2 trial of (LY3884961) GBA1 gene therapy for Gaucher disease type 1
Gene therapy, neurological, metabolic, Parkinson's disease, Gaucher disease, GBA1 - Read more

Novo Nordisk's upbeat forecast overshadowed by oral Wegovy sales miss and CagriSema Phase III disappointment
Small molecule, metabolic disease, financial, competitive - Read more

Amgen discontinues early-stage obesity drug AMG 513, shifting full weight-loss focus to MariTide
Antibody-peptide conjugate, obesity, strategic, pipeline - Read more

Pfizer expands cost-cutting program to $6.7B in savings amid ongoing post-COVID revenue decline
Cost reduction, infectious disease, financial, operational - Read more

Amgen discontinues AMG 513, leaving MariTide as sole obesity pipeline candidate amid M&A disappointment
Antibody-peptide conjugate, obesity, cardiometabolic, strategic - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here